Biotech funding this quarter: the 2026 healthcare data cut

The most recent fully measured quarter is Q2 2026: biopharma venture funding reached $10.5 billion (PitchBook), medtech $4.9 billion (PitchBook), and digital health fell 24% to $5.7 billion (CB Insights). Each of those totals is dominated by a handful of mega-rounds.

Data on this page is current as of 7 August 2026. PitchBook, CB Insights and Carta report life sciences investment quarterly, not weekly, so "this quarter" here means the last complete reported quarter: Q2 2026, covering April to June. Every figure below carries the period it describes. Anything announced since the quarter closed is a press release, not a measured total, and it is not counted.

A single healthcare funding number is three different markets averaged into a figure that describes none of them. Therapeutics, devices and digital health have different buyers, different timelines and a valuation logic tied to clinical stage rather than ARR. They moved in different directions inside the same quarter.

Healthcare VC funding in 2026, split by subsector

Read the scopes before you read the numbers. PitchBook's healthtech and CB Insights' digital health are overlapping but different definitions, the reports differ on geography and on what counts as venture funding, and the Carta seed median is drawn from companies on Carta. Comparing across those rows is a direction check, not arithmetic.

Why biotech seed rounds and biotech valuations break the software rules

PitchBook does not include pharma and biotech in its technology-seed valuation analysis at all, because their capital intensity, regulatory pathways and progress measures differ fundamentally from technology startups (PitchBook analyst note, Q4 2025). If the people who build the benchmarks refuse to put you in the same bucket as SaaS, do not price your round off a SaaS comparable.

• Fewer seeds, larger seeds: biotech companies receive fewer seed investments than other healthcare segments, but those financings are generally larger and higher stakes (SVB).
• More dilution for the same round label: healthcare seed dilution was 20% in Q1 2025, with pharma and biotech at 21.5% against healthcare tech at 16.4% (Carta, Q1 2025). A therapeutics founder gives up more of the company than a healthcare-tech founder for a round carrying the same name.
• The only public seed median is a proxy: the median healthcare seed round was $2 million in Q4 2024, down 30% from the same quarter of 2023 (Carta). That covers all healthcare, so use it as a sanity floor, never as a therapeutics target.

Digital health funding is recovering, but the recovery is ten companies

Digital health funding is up year over year and down quarter over quarter, and the second fact is the one that affects your raise. Funding rose to $7.4 billion in Q1 2026 from $5.9 billion in Q4 2025, its highest level since Q2 2022, with 19 mega-rounds capturing 60% of all funding (CB Insights, Q1 2026). In Q2 2026 it fell 24% to $5.7 billion, and 60% of that went to just 10 mega-rounds (CB Insights, Q2 2026).

Track deal count, not dollars, because deal count is your odds. Digital-health funding grew for the second consecutive year in 2025, but deal volume fell 9% as investors shifted toward fewer, more mature companies (CB Insights, 2025). A rising total with a falling deal count means the money is moving past first-time raisers.

AI is where the healthcare money concentrated. Healthcare AI attracted nearly $18 billion of US and European VC investment in 2025, 46% of all healthcare investment (SVB). The same skew shows up at the entry point: about 3,000 US startups raised more than $2.3 billion in pre-seed on Carta in Q1 2026, with AI startups taking 50% of pre-seed dollars (Carta State of Pre-Seed, Q1 2026).

Medtech and devices: one financing wrote the headline

The Q2 2026 medtech total is not a device-round benchmark. Medtech VC funding reached $4.9 billion in Q2 2026, up from $3.7 billion in Q1 2026, and surgical devices and tools accounted for about $3 billion across 78 deals. The quarter was heavily influenced by a single $1.5 billion later-stage MiRus financing, so the sector total should not be read as a typical device round (PitchBook, Q2 2026).

Stability, not size, is the useful signal here. SVB separates healthcare into biopharma, healthtech, diagnostics and tools, and devices, and found healthtech and devices more stable while biopharma declined and diagnostics and tools remained under pressure (SVB H1 2026). A steady subsector with smaller cheques is an easier raise than a headline subsector carrying one outlier.

What this data should change about who you pitch

Change your target list, not your pitch. Biopharma capital in Q2 2026 concentrated in later-stage, de-risked opportunities, with the early-stage share of deal value tracking toward a record low (PitchBook, Q2 2026). If you are pre-clinical, the generalist funds reading that quarter are not your buyers this cycle, and the subsector specialists are.

Market data tells you what is normal. It does not tell you which funds are actually deploying into your stage and subsector right now. Causo matches you to the investors most likely to fund you and drafts the outreach.

Start from the active US healthcare seed investors list, then read the biotech seed fundraise guide if you are on a therapeutics path, or medtech vs digital health fundraising if your product has a device or a software surface.

FAQ

What is a typical biotech seed round? No firm publishes a biotech-only seed median. The closest public benchmark is Carta's healthcare seed median of $2 million in Q4 2024, down 30% from the same quarter of 2023, and it spans all of healthcare rather than biotech alone. SVB reports that biotech companies receive fewer seed investments than other healthcare segments, but those financings are generally larger and higher stakes, so treat $2 million as a floor for expectations rather than a target.

Is digital health funding recovering in 2026? Partly. CB Insights recorded $7.4 billion in Q1 2026, the highest quarterly level since Q2 2022, then a 24% fall to $5.7 billion in Q2 2026. Concentration is the bigger story: 60% of Q2 2026 funding went to just 10 mega-rounds, and deal volume across 2025 fell 9% as investors shifted toward fewer, more mature companies.

How much funding does a biotech startup need? The amount is set by your next clinical or regulatory milestone, not by a market average, and no source here publishes a biotech-only figure. The nearest public anchor is Carta's $2 million median healthcare seed round in Q4 2024, which covers all healthcare. Carta also measured pharma and biotech seed dilution at 21.5% in Q1 2025 against 16.4% for healthcare tech, so the round is both larger and more expensive in ownership terms.

Which healthcare subsectors receive the most VC funding? In Q2 2026, biopharma was the largest at $10.5 billion, ahead of digital health at $5.7 billion and medtech at $4.9 billion. SVB's H1 2026 report splits healthcare into biopharma, healthtech, diagnostics and tools, and devices, finding healthtech and devices more stable while biopharma declined. AI cuts across all of them: healthcare AI took nearly $18 billion of US and European VC investment in 2025, 46% of all healthcare investment.

What is the difference between biotech and digital-health funding? They are different asset classes measured on different clocks. Biopharma rounds are gated on clinical and regulatory milestones, which is why PitchBook excludes pharma and biotech from its technology-seed valuation analysis. Digital health is measured like a software market and swings with mega-round timing, falling 24% to $5.7 billion in Q2 2026 while biopharma reached $10.5 billion. Dilution differs too: Carta measured 21.5% pharma and biotech seed dilution in Q1 2025 against 16.4% for healthcare tech.

Related on the hub

• Seed healthcare VCs US: who writes first checks in 2026 — Seed healthcare VCs US founders can pitch in 2026: active firms leading digital health, medtech, and…
• Biotech seed fundraise 2026: platform vs asset, tranches, milestones — Related fundraising basics guide.
• The H1 2026 AI startup funding report — Related fundraising basics guide.
• AI Startup Funding This Quarter: Deals, Sizes, Valuations — Related fundraising basics guide.